Rhythm Seeks to Test Setmelanotide in More Obesity Disorders This Year

Rhythm Seeks to Test Setmelanotide in More Obesity Disorders This Year

284924

Rhythm Seeks to Test Setmelanotide in More Obesity Disorders This Year

Rhythm Pharmaceuticals has identified 31 additional genes whose mutations may be amenable to setmelanotide, its U.S.-approved therapy for genetic obesity disorders linked to the melanocortin-4 receptor (MC4R) pathway. This discovery is the result of Rhythm’s sequencing efforts and precision approach that has been recently validated in a Phase 2 basket study (NCT03013543), leading to the identification of several new MC4R-related disorders with promising responses to setmelanotide. “Leveraging our extensive scientific expertise and years of internal research,…

You must be logged in to read/download the full post.